drug
palbociclib
Marketedupdated 6mo agoby $OTLC Oncotelic Therapeutics, Inc.
Approvedannual revenue · 2024–2024peak $4.4B
community read0 votes
🐶 often sniffed alongside
top 2indications
investigational
Breast Cancer
all catalysts(0)
nothing on the calendar yet
Trials studying palbociclib
- phase1A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
- —A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
- phase3Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- phase2A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
- phase2A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
- —Swedish Ibrance Registries Insights (SIRI)
- phase2Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
- phase3Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 5, 2027
105 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (30)
- Feb 19, 2037patentUS 11065250*PED
- Feb 19, 2037patentUS 11065250*PED
- Feb 19, 2037patentUS 11065250*PED
- Aug 19, 2036formulationUS 11065250
- Aug 19, 2036formulationUS 11065250
- Aug 19, 2036formulationUS 11065250
- Aug 8, 2034patentUS 10723730*PED
- Aug 8, 2034patentUS 10723730*PED
- Aug 8, 2034patentUS 10723730*PED
- Aug 8, 2034patentUS 10723730*PED
- Aug 8, 2034patentUS 10723730*PED
- Aug 8, 2034patentUS 10723730*PED
- Feb 8, 2034compositionUS 10723730
- Feb 8, 2034compositionUS 10723730
- Feb 8, 2034compositionUS 10723730
- Feb 8, 2034compositionUS 10723730
- Feb 8, 2034compositionUS 10723730
- Feb 8, 2034compositionUS 10723730
- Sep 5, 2027patentUS RE47739*PED289d
- Sep 5, 2027patentUS RE47739*PED289d
- Sep 5, 2027patentUS RE47739*PED289d
- Sep 5, 2027patentUS RE47739*PED289d
- Sep 5, 2027patentUS RE47739*PED289d
- Sep 5, 2027patentUS RE47739*PED289d
- Mar 5, 2027compositionUS RE47739105d
- Mar 5, 2027compositionUS RE47739105d
- Mar 5, 2027compositionUS RE47739105d
- Mar 5, 2027compositionUS RE47739105d
- Mar 5, 2027compositionUS RE47739105d
- Mar 5, 2027compositionUS RE47739105d
FDA exclusivities (12)
- Mar 16, 2029PEDPediatric (6mo bonus)2.3y
- Mar 16, 2029PEDPediatric (6mo bonus)2.3y
- Mar 16, 2029PEDPediatric (6mo bonus)2.3y
- Mar 16, 2029PEDPediatric (6mo bonus)2.3y
- Mar 16, 2029PEDPediatric (6mo bonus)2.3y
- Mar 16, 2029PEDPediatric (6mo bonus)2.3y
- Sep 16, 2028M-14Method (3y)1.8y
- Sep 16, 2028M-14Method (3y)1.8y
- Sep 16, 2028M-14Method (3y)1.8y
- Sep 16, 2028M-14Method (3y)1.8y
- Sep 16, 2028M-14Method (3y)1.8y
- Sep 16, 2028M-14Method (3y)1.8y
News(10)
- Blackstone bets $1.5B on Pfizer’s obesity drugThe deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.biopharma_dive · 6d ago
- AstraZeneca’s newly approved cancer pill fails late-stage study, blocking path to bigger marketSERENA-4 was assessing AstraZeneca’s Etcamah as a first-line option for certain patients with advanced breast cancer—a setting that could have meant a $2.9 billion opportunity for the drug.biospace · 2mo ago
- AstraZeneca’s SERD pill overcomes adcomm defeat to win FDA nod in breast cancerThe approval opens up a “modest” market for AstraZeneca’s Etcamah, according to Leerink analysts, who nevertheless looked forward to an upcoming late-stage readout that could lead to a “significant…biospace · 2mo ago
- FDA Grants Accelerated Approval to a New Breast Cancer TreatmentThe U.S. Food and Drug Administration today expanded treatment options for adult patients with advanced breast cancer, reflecting the FDA’s commitment to advancing medical innovation and getting ne…fda_press · 2mo ago
- Pfizer expands multibillion-dollar cost-cutting planHatched three years ago, the restructuring is now expected to deliver $1 billion in new cost reductions and save Pfizer another $1.5 billion by streamlining drug production.biopharma_dive · 3mo ago
- Celcuity gains FDA approval for closely watched breast cancer drugStill, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s prescribing information surprised some analysts, too.biopharma_dive · 4mo ago
- Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trialGedatolisib could “establish a new standard of care” for PIK3CA-mutated breast cancer, an investigator said, but the results nonetheless appeared to disappoint investors.biopharma_dive · 5mo ago
- RallyBio tries again for reverse merger, this time with AvenzoIt's the second attempt for the rare disease company, which initially announced plans to merge with Candid Therapeutics before the immune drug developer was bought by UCB.biopharma_dive · 5mo ago
- The OncFive: Top Oncology Articles for the Week of 5/3The FDA clears zenocutuzumab in NRG1 fusion+ cholangiocarcinoma, accepts a taletrectinib NDA in ROS1+ NSCLC for review, and more.onclive · 6mo ago
- Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ASCO 2026.onclive · 6mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that